We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

MINDRAY In-Vitro Diagnostics

  Gold Mindray offers a range of chemistry and hematology analyzers, designed to meet the needs of smaller labs as a main in... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

Diagnostic Value of Hematology Parameters Investigated for Hemophagocytic Lymphohistiocytosis

By LabMedica International staff writers
Posted on 04 Aug 2021
Print article
Image: Mindray Double Chamber BC-5130 Auto Hematology Analyzer (Photo courtesy of Mindray)
Image: Mindray Double Chamber BC-5130 Auto Hematology Analyzer (Photo courtesy of Mindray)
Hemophagocytic lymphohistiocytosis (HLH) is a severe rare syndrome characterized by pathologic immune activation and hyperinflammation with harmful effects on multiple organs. The clinical presentations of HLH may include fever, cytopenias, splenomegaly, and hyperferritinemia, none of which is specific for this rare though life-threatening condition.

HLH shares similarities with other inflammatory states, for example, sepsis, and the high inflammatory response present in both states of HLH and sepsis provides overlapping clinical features, including fever and worsening clinical status. The differential diagnosis of HLH and sepsis is critically important because the life-saving aggressive immunosuppressive treatment, required in the effective HLH therapy, is absent in sepsis guidelines.

Clinical Laboratorians at the Zhejiang University School of Medicine (Hangzhou, China) conducted a retrospective study, involving 71 HLH patients, 105 sepsis patients, and 88 normal controls from January 2018 to December 2019. Children were classified as HLH if they meet at least five of the eight criteria of the International Histiocyte Society (2004-HLH criteria).

Peripheral blood samples were collected from all the participants for the first time. After treatment, peripheral blood samples from HLH patients were also collected. Complete blood counts were analyzed by hematology analyzer BC-5310 (Mindray, Nanshan, China). Red blood cell distribution width (RDW) and platelet distribution width (PDW) levels were collected from patients’ complete blood count, and RDW to platelet count ratio (RPR) was calculated as the ratio of RDW and platelet counts.

The scientists reported that nearly all the patients demonstrated fever and splenomegaly were present in more than 90% of the patients (fever: 70/71, 98.59%; splenomegaly: 68/71, 95.77%). Other clinical and laboratory tests included anemia (44/71, 61.97%), neutropenia (38/71, 53.52%), thrombocytopenia (33/71, 46.48%), hypofibrinogenemia (44/71, 61.97%), hypertriglyceridemia (28/71, 39.44%), hyperferritinemia (49/71, 69.01%), impaired NK-cell activity (47/71, 66.20%), and hemophagocytosis (20/24, 83.33%).

RDW, PDW, and RPR levels of the HLH patients were significantly higher than those of sepsis and normal controls. In ROC curve analysis of the RDW, PDW, and RPR for diagnosis of HLH, the area under the curve (AUC) reached to 0.78, 0.784, and 0.927, respectively. When using the criteria of RDW >13.75, PDW >13.30, and RPR >0.08, the sensitivity was 76.06%, 67.61%, and 84.51%, while the specificity was 68.57%, 85.71%, and 87.62%, respectively. After treatment of HLH patients, PDW and RPR were significantly reduced.

The authors concluded that their study indicated that cost-effective and easily calculated hematological parameters RDW, PDW, and RPR are novel indicators for differential diagnosis of HLH and sepsis. PDW and RPR could be additional biomarkers for monitoring therapeutic effects of HLH. The study was published on July 17, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:

Zhejiang University School of Medicine
Mindray


New
Gold Supplier
Molecular Diagnostic System
Singuway 9600 Pro
New
Gold Supplier
Fluorimetric Immunoassay Analyzer
Confiscope F20
New
Silver Supplier
SARS-CoV-2 Antigen Test
NG-Test SARS-NG-Test SARS-CoV-2 Ag Cassette
New
Silver Supplier
SARS-CoV-2 RT-PCR Assay
Savvygen SARS-CoV-2 Plus

Print article

Channels

Clinical Chem.

view channel
VIASURE HLA Celiac Real Time PCR Detection Kit

CerTest VIASURE HLA Celiac RT PCR Kit Enables Rapid Resolution of HLA Haplotypes Associated with Celiac Disease

CerTest Biotec (Zaragoza, Spain) has developed a simple and ready to use real-time PCR for the detection of the principal alleles of the HLA system and the subsequent determination of the DQ2 and DQ8 antigens... Read more

Immunology

view channel
Illustration

First-Of-Its Kind Blood Test to Distinguish between Bacterial and Viral Infections Using Body’s Immune Response Granted FDA Clearance

A first-of-its kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes has been granted clearance by the US Food and Drug Administration (FDA).... Read more

Pathology

view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more

Industry

view channel
Illustration

Thermo Fisher Launches World’s First Fully Integrated Digital PCR (dPCR) System

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched the world’s first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.